An example of how testing the appropriate NOD congenic strain might have produced a different result to standard NOD mice and predicted the failure of a T1D treatment is low-dose IL-2 therapy, which increases the frequency of Tregs but has not been able to produce positive effects on diabetes in patients (78). The gene discussed is IL2; the disease is type 1 diabetes mellitus.